Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
Provectus reported positive preclinical data for oral PV-10 in an orthotopic bladder cancer model, where the monotherapy arm ranked highest in a weighted scoring framework. Two animals treated with oral PV-10 survived to the study end with no gross bladder tumor at necropsy, a finding not seen in control or anti-PD-1 monotherapy groups. The oral route demonstrated superior tolerability with a body weight nadir of -1.9%, whereas the intravesical route failed due to acute mucosal toxicity at the tested concentrations.
Key figures
- Drug Name
- PV-10
- Total mice
- 54
- Study duration days
- 45
- Long term survivors oral
- 2
- Oral pv10 weighted score
- 9.24
- Oral pv10 body weight nadir
- -1.9%
- Oral pv10 tumor burden reduction
- 40%
- Oral pv10 plus pd1 weighted score
- 7.84
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.